Case Number:

PGR2021-00042

Case Type:

PGR

Status:

Terminated-Adverse Judgment

Petitioner:

Daiichi Sankyo, Inc.

1. Filed: January 22, 2021 00:00

   Coverage

   1. April 08, 2022

      PTAB To Review Cancer Antibody IP That Drew $41.8M Verdict

      The Patent Trial and Appeal Board has agreed to review a Seagen Inc. antibody patent after the board previously used its discretion to reject two challenges from Daiichi Sankyo Inc. and AstraZeneca while a Texas federal jury on Friday found Daiichi willfully infringed the patent to the tune of $41.8 million.

   1 other articles on this case. View all »

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login